tumor necrosis factor receptor 2 antagonist

Tumor necrosis factor receptor 2 (TNFR2) antagonists are a class of therapeutic agents, primarily monoclonal antibodies, designed to inhibit the signaling of TNFR2 (TNFRSF1B). TNFR2 is a member of the TNF receptor superfamily that is predominantly expressed on immunosuppressive immune cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as on certain highly aggressive tumor cells. Unlike TNFR1, which is ubiquitously expressed and often associated with pro-inflammatory and apoptotic pathways, TNFR2 signaling promotes the survival and suppressive function of Tregs, contributing to an immunosuppressive tumor microenvironment and effector T cell exhaustion. By antagonizing TNFR2, these agents aim to selectively deplete or inhibit suppressive cell populations and reinvigorate anti-tumor immune responses, particularly CD8+ T cell activity. Preclinical research, including studies in glioblastoma, has demonstrated that TNFR2 blockade can reduce the expression of terminal exhaustion markers like TOX and improve the efficacy of other immunotherapies. Several TNFR2 antagonists, such as BI-1808 and BMS-986179, have entered clinical evaluation for solid tumors and hematological malignancies.

Other names

TNFR2 antagonistTNFR-2 antagonistTNFR 2 antagonistTNFR2 inhibitorTNFR-2 inhibitorTNFR 2 inhibitorTNFRII antagonistanti-TNFR2 antibodyanti-TNFR-2 antibodyanti-TNFR 2 antibody